Navigation Menu



Learn about Grifols, a global healthcare company


The Coalition for Hemophilia B

The Coalition for Hemophilia B  was founded in 1990 as a way to provide information about treatment options to patients and families.

National Hemophilia Foundation

The National Hemophilia Foundation (NHF) is dedicated to finding better treatments and cures for bleeding and clotting disorders and preventing the complications of these disorders through education, advocacy, and research.

Hemophilia Federation of America

Hemophilia Federation of America (HFA) was founded in 1994 to address the evolving needs of the bleeding - disorders community.

World Federation of Hemophilia

The World Federation of Hemophilia (WFH) is an international not-for-profit organization dedicated to improving the lives of people with hemophilia and related bleeding disorders.

LA Kelley Communications

LA Kelley Communications creates and provides free resources to help patients and parents master the often overwhelming world of chronic bleeding disorders such as hemophilia. Clear and comprehensive resources encourage patients and parents to be proactive in their healthcare.

Hope for Hemophilia

Hope for Hemophilia is a not-for profit organization with the mission to serve as a conduit of hope, strength and resource to individuals and their families through seasons of crisis caused by hemophilia.



AlphaNine® SD (coagulation factor IX [human]) is indicated for the prevention and control of bleeding in patients with Factor IX deficiency due to hemophilia B.


AlphaNine SD is made from human plasma. Plasma products carry a risk of transmitting infectious agents, including viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.

Incidences of thrombosis or disseminated intravascular coagulation (DIC) have been reported following administration of Factor IX Complex concentrates which contain high amounts of Factor II, VII, and X. AlphaNine SD contains low, nontherapeutic levels of Factor II, VII, and X.

Following administration in surgery patients and individuals with known liver disease, the physician should closely observe the patient for signs and symptoms of potential disseminated intravascular coagulation.

Allergic type hypersensitivity reactions, including anaphylaxis, have been reported for all factor IX products. The administration of plasma preparations may cause allergic reactions, mild chills, nausea or stinging at the infusion site.

Nephrotic syndrome has been reported following attempted immune tolerance induction with factor IX products in hemophilia B patients with factor IX inhibitors and a history of severe allergic reactions to Factor IX.

In order to minimize the possibility of thrombogenic complications, dosing guidelines should be strictly followed.

AlphaNine SD should not be administered at a rate exceeding 10 mL/ minute. Rapid administration may result in vasomotor reactions.

Please see full Prescribing Information for AlphaNine SD.